Lyft's Booking Boom Clouded by Short Seller Drama as Dominion's Mega-Merger Faces PushbackGlobal Report·Aug 18 at 04:44 AMLYFT-0.76%OST0.00%
MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial AdvancesTradingKey·Aug 14 at 03:24 AMINKT-1.44%
INKT: Phase 2 trial of agenT-797 showed early clinical benefit; cash at $8.8M, net loss narrowedQuartr·Aug 13 at 06:42 AMINKT-1.44%
MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trialPUBT·Aug 6 at 11:01 AMINKT-1.44%
Mink Therapeutics to report Q2 results, host conference call and webcastPUBT·Aug 6 at 07:19 AMINKT-1.44%
MiNK Therapeutics (INKT) Projected to Post Earnings on ThursdayMarket Beat·Aug 6 at 01:56 AMINKT-1.44%
INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expandedQuartr·Jun 17 at 09:49 AMINKT-1.44%
